Intranasal adrenaline: A new treatment for anaphylaxis - PubMed
2 days ago
- #needle-free delivery
- #pediatric allergy
- #anaphylaxis
- Intranasal adrenaline offers a needle-free alternative for anaphylaxis treatment, addressing needle phobia and technical challenges in children.
- Three leading intranasal adrenaline products are highlighted: neffy® (FDA-approved), UTULY™ (high-dose strategy), and FMXIN002 (microsphere powder technology).
- Pharmacokinetic studies show intranasal adrenaline achieves comparable or superior plasma concentrations to intramuscular injections, with faster absorption.
- A Phase 3 clinical study in pediatric patients demonstrated effective symptom resolution in a median time of 16 minutes with no serious adverse events.
- Nasal congestion and upper respiratory infections enhance adrenaline absorption, contrary to initial concerns.
- Advantages include simplified administration, enhanced thermal stability, and elimination of injection-related barriers.
- Intranasal adrenaline is particularly beneficial for pediatric populations with prevalent injection anxiety.